Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, sec-filing
Related Tickers: AQST
TL;DR
AQST filed an 8-K, standard disclosure, no major news.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on June 2, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial details or new material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing indicates Aquestive Therapeutics is providing standard disclosures and financial information to the SEC, which is routine for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any new material risks or events.
Key Numbers
- 20250602 — Report Date (Date of the 8-K filing)
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- 0001398733 (company) — Central Index Key
- 208623253 (company) — EIN
- MonoSol Rx, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Aquestive Therapeutics?
The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on June 2, 2025.
What is Aquestive Therapeutics' state of incorporation?
Aquestive Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Aquestive Therapeutics?
The principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
Does this filing indicate any specific new financial results or material events?
No, this filing is a standard 8-K for disclosures and exhibits and does not detail specific new financial results or material events.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Aquestive Therapeutics, Inc. (AQST).